Trial reportPituitary2016
Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study.
Trial report in Pituitary, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05206149 (Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes
Who cites it
30 citing papers in PubMed.
- GH Response to Glucagon in Transition: Role of Body Mass Index and Etiology in Childhood-onset GH Deficiency.The Journal of clinical endocrinology and metabolism · 2026Article
- Comparison of Glucagon Stimulation Test and Insulin Tolerance Test for Assessment of an Anterior Pituitary Function-A Cross-Over Study.Journal of clinical medicine · 2025Article
- The history of an effective, specific and sensitive diagnostic test: the GHRH test in clinical practice.Reviews in endocrine & metabolic disorders · 2025Review
- Accuracy of Glucagon Testing Across Transition in Young Adults With Childhood-Onset GH Deficiency.The Journal of clinical endocrinology and metabolism · 2024Article
- A 2024 Update on Growth Hormone Deficiency Syndrome in Adults: From Guidelines to Real Life.Journal of clinical medicine · 2024Review
- Once upon a time: the glucagon stimulation test in diagnosing adult GH deficiency.Journal of endocrinological investigation · 2024Review
- A Contemporary Approach to the Diagnosis and Management of Adrenal Insufficiency.Endocrinology and metabolism (Seoul, Korea) · 2024Review
- Policy for transitioning childhood-onset growth hormone deficiency from pediatric to adult endocrine care in Belgium.Frontiers in endocrinology · 2024Review
- Determination of glucose cut-off points for optimal performance of glucagon stimulation test.Frontiers in endocrinology · 2024Article
- Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis.Endocrine connections · 2023Review
- Current Screening Strategies for the Diagnosis of Adrenal Insufficiency in Children.Pediatric health, medicine and therapeutics · 2023Review
- Limited Role of Endogenous Vasopressin/Copeptin in Stimulation of ACTH-Cortisol Secretion during Glucagon Stimulation Test in Humans.Biomedicines · 2022Article
- Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.European journal of endocrinology · 2022Review
- Cortisol values during the standard-dose cosyntropin stimulation test: Personal experience with Elecsys cortisol II assay.Frontiers in endocrinology · 2022Article
- Investigation of the Hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis.Reviews in endocrine & metabolic disorders · 2021Review
- Comparison of a combination test (1 μg ACTH test plus glucagon test) versus 1 μg ACTH test and glucagon test in the evaluation of the hypothalamic-pituitary-adrenal axis in patients with pituitary disorders.Archives of endocrinology and metabolism · 2021Article
- Experience of a Pituitary Clinic for US Military Veterans With Traumatic Brain Injury.Journal of the Endocrine Society · 2021Article
- Adrenal insufficiency.Nature reviews. Disease primers · 2021Review
- Current concepts of the diagnosis of adult growth hormone deficiency.Reviews in endocrine & metabolic disorders · 2021Review
- Sensitivity and specificity of the macimorelin test for diagnosis of AGHD.Endocrine connections · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextRecent studies suggest using lower GH cut-points for the glucagon stimulation test (GST) in diagnosing adult GH deficiency (GHD), especially in obese patients. There are limited data on evaluating GH and hypothalamic-pituitary-adrenal (HPA) axes using weight-based dosing for the GST.
objectiveTo define GH and cortisol cut-points to diagnose adult GHD and secondary adrenal insufficiency (SAI) using the GST, and to compare fixed-dose (FD: 1 or 1.5 mg in patients >90 kg) with weight-based dosing (WB: 0.03 mg/kg). Response to the insulin tolerance test (ITT) was considered the gold standard, using GH and cortisol cut-points of ≥3 ng/ml and ≥18 µg/dL, respectively.
design28 Patients with hypothalamic-pituitary disease and 1-2 (n = 14) or ≥3 (n = 14) pituitary hormone deficiencies, and 14 control subjects matched for age, sex, estrogen status and body mass index (BMI) underwent the ITT, FD- and WB-GST in random order.
resultsAge, sex ratio and BMI were comparable between the three groups. The best GH cut-point for diagnosis of GHD was 1.0 (92 % sensitivity, 100 % specificity) and 2.0 ng/mL (96 % sensitivity and 100 % specificity) for FD- and WB-GST, respectively. Age negatively correlated with peak GH during FD-GST (r = -0.32, P = 0.04), but not WB-GST. The best cortisol cut-point for diagnosis of SAI was 8.8 µg/dL (92 % sensitivity, 100 % specificity) and 11.2 µg/dL (92 % sensitivity and 100 % specificity) for FD-GST and WB-GST, respectively. Nausea was the most common side effect, and one patient had a seizure during the FD-GST.
conclusionThe GST correctly classified GHD using GH cut-points of 1 ng/ml for FD-GST and 2 ng/ml for WB-GST, hence using 3 ng/ml as the GH cut-point will misclassify some GH-sufficient adults. The GST may also be an acceptable alternative to the ITT for evaluating the HPA axis utilizing cortisol cut-points of 9 µg/dL for FD-GST and 11 µg/dL for WB-GST.
Indexed as
Identifiers
26897383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.